^
    almost4years
    The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. (PubMed, Pharmacol Res)
    Similarly, dovitinib, AZD4547, CH5183284, infigratinib, lenvatinib, LY2874455, and lucitanib are type I½ inhibitors...Ponatinib binds to FGFR4 in a DFG-D conformation and is classified as a type II inhibitor. Futibatinib, roblitinib, H3B-6527, fisogatinib, and PRN1371 bind covalently to their FGFR target and are classified as type VI inhibitors. Nintedanib, pazopanib, pemigatinib, rogaratinib, fisogatinib, and PRN1371 are FGFR inhibitors lacking drug-enzyme crystal structures...The development of FGFR inhibitors has lagged behind those of other receptor protein-tyrosine kinases. However, the FDA approval of erdafitinib for the treatment of urinary bladder cancers may stimulate additional work targeting the many other FGFR-driven neoplasms.
    Review • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FLT1 (Fms-related tyrosine kinase 1) • CSF1R (Colony stimulating factor 1 receptor)
    |
    Iclusig (ponatinib) • Lenvima (lenvatinib) • pazopanib • Balversa (erdafitinib) • Truseltiq (infigratinib) • Lytgobi (futibatinib) • Pemazyre (pemigatinib) • fexagratinib (ABSK091) • rogaratinib (BAY 1163877) • nintedanib • zoligratinib (Debio 1347) • dovitinib (TKI258) • fisogatinib (BLU-554) • lucitanib (E 3810) • H3B-6527 • roblitinib (FGF401) • PRN1371 • LY2874455